Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing

European Journal of Clinical Pharmacology

Volumn 61, Issue 12, 2005, Pages 887-892

  Skarke, Garsten ^a   Kirchhof, Anja ^a   Geisslinger, Gerd ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

CYP1A2; Pharmacogenetics; Pyrosequencing

Indexed keywords

CYTOCHROME P450 1A2;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; ETHNOLOGY; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC SCREENING; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY CONTROL; RELIABILITY; REPRODUCIBILITY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL DISTRIBUTION; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ALLELES; CYTOCHROME P-450 CYP1A2; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 29144441009     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0029-3     Document Type: Article

References (31)

1. Brosen K (1995) Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet 29 (Suppl 1):20-25
2. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47(4):445-449
3. Nordmark A, Lundgren S, Ask B, Granath F, Rane A (2002) The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 54(5): 504-510
4. Aklillu E, Carrillo JA, Makonnen E, et al (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64(3):659-669
5. Shimoda K, Someya T, Morita S, et al (2002) Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 26(2):261-265
6. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 125(4):803-808
7. Allorge D, Chevalier D, Lo-Guidice JM, et al (2003) Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 56(3):341-344
8. Murayama N, Soyama A, Saito Y, et al (2004) Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 308(1):300-306
9. Sachse C, Bhambra U, Smith G, et al (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55(1):68-76
10. Ronaghi M (2001) Pyrosequencing sheds light on DNA sequencing. Genome Res 11(1):3-11
11. Lewontin RC (1964) The interaction of selection and linkage. II. Optimum models. Genetics 50:757-782
12. Gaut BS, Long AD (2003) The lowdown on linkage disequilibrium. Plant Cell 15(7):1502-1506
13. Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73(5):1162-1169
14. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978-989
15. Soyama A, Saito Y, Hanioka N, et al (2005) Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 20(1):24-33
16. Dandara C, Basvi PT, Bapiro TE, Sayi J, Hasler JA (2004) Frequency of -163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clin Chem Lab Med 42(8):939-941
17. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T (1999) Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90(9):899-902
18. Basile VS, Ozdemir V, Masellis M, et al (2000) A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5(4):410-417
19. Christiansen L, Bygum A, Jensen A, et al (2000) Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet 107(6):612-614
20. Aitchison KJ, Gonzalez FJ, Quattrochi LC, et al (2000) Identification of novel polymorphisms in the 5′ flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics 10(8):695-704
21. Han XM, Ou-Yang DS, Lu PX, et al (2001) Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 11(5):429-435
22. Goodman MT, McDuffie K, Kolonel LN, et al (2001) Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 10(3):209-216
23. Cornelis MC, El-Sohemy A, Campos H (2004) Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 41(10):758-762
24. Schrenk D, Brockmeier D, Morike K, Bock KW, Eichelbaum M (1998) A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol 53(5):361-367
25. Rasmussen BB, Brosen K (1996) Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 18(3):254-262
26. Hamdy SI, Hiratsuka M, Narahara K, et al (2003) Genotyping of foui- genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 55(3):321-324
27. Todesco L, Torok M, Krahenbuhl S, Wenk M (2003) Determination of -3858G->A and -164C->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G->A mutation between Caucasians and Asians. Eur J Clin Pharmacol 59(4):343-346
28. Han XM, Chen XP, Wu QN, Jiang CH, Zhou HH (2000) G-2964A and C734A genetic polymorphisms of CYP1A2 in Chinese population. Acta Pharmacol Sin 21(11):1031-1034
29. Han XM, Ouyang DS, Chen XP, et al (2002) Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 54(5):540-543
30. Goodman MT, Tung KH, McDuffie K, Wilkens LR, Donlon TA (2003) Association of caffeine intake and CYP1A2 genotype with ovarian cancer. Nutr Cancer 46(1):23-29
31. Schulze TG, Schumacher J, Muller DJ, et al. (2001) Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 105(6):498-501